References
- Amarenco P, Lavalle'e P, Touboul P-J. Stroke prevention, blood cholesterol, and statins. Lancet Neurol. 2004; 3: 271–8
- Wahner AD, Bronstein JM, Bordelon YM, Ritz B. Statin use and the risk of Parkinson's disease. Neurology. 2008; 70: 1418–22
- Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer's disease associated with 3-hydroxyl-3-methylglutaryl-cienzyme A reductase inhibitors. Arch Neurol. 2000; 57: 1439–43
- Li G, Larson EB, Sonnen JA, Shofer JB, Petrie EC, Schantz A, et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer's disease. Neurology. 2007; 69: 878–85
- Kumagai R, Oki C, Muramatsu Y, Kurosaki R, Kato H, Araki T. Pitavastatin, a 3-hydroxyl-3-methylglutaryl-cienzyme A (HMG-CoA) reductase inhibitor, reduces hippocampal damage after transient cerebral ischemia in gerbils. J Neurol Transm. 2004; 111: 1103–20
- Chen J, Zhang C, Jiang H, Li Y, Zhang L, Robin A, et al. Atorvastatin induction of VEGF and BDNF promotes brain plasticity after stroke in mice. J Cereb Blood Flow Metab. 2005; 25: 281–90
- Selley ML. Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- induced dopamine depletion and protein tyrosine nitration in mice. Brain Res. 2005; 1037: 1–6
- Youssef S, Stu”eb O, Patarroyo JC, Rulz PC, Radosevich JL, Hur EM, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002; 420: 78–84
- Wang H, Lynch JR, Song P, Yang H-J, Yates RB, Mace B, et al. Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury. Exp Neurol. 2007; 206: 59–69
- Pannu R, Barbosa E, Singh AK, Singh I. Attenuation of acute inflammatory response by atorvastatin after spinal cord injury in rats. J Neurosci Res. 2005; 1: 340–50
- Zinman L, Sadeghi R, Gawel M, Patton D, Kiss A. Are statin medications safe in patients with ALS. Amyotroph Lateral Scler. 2008; 9: 223–8
- Drory VE, Bronipolsky T, Artamonov I, Nefussy B. Influence of statins treatment on survival in patients with amyotrophic lateral sclerosis. J Neurol Sci. 2008; 273: 81–3
- Ikeda K, Iwasaki Y, Kinoshita M, Marubuchi S, Ono S. T-588, a novel neuroprotective agent, delays progression of neuromuscular dysfunction in wobbler mouse motor neuron disease. Brain Res. 2000; 858: 84–91
- Scmitt-John T, Drepper C, Mussmann A, Hahn P, Kuhlmann M, Thiel C, et al. Mutation of Vps54 causes motor neuron disease and defective spermiogenesis in the wobbler mouse. Nat Genet. 2005; 37: 1213–5
- Mitsumoto H, Ikeda K, Klinkosz B, Cedarbaum JM, Wong V, Lindsay RM. Arrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNF. Science. 1994; 265: 1107–10
- Ikeda K, Kinoshita M, Iwasaki Y, Tagaya N, Shiojima T. Lecithinized superoxide dismutase retards wobbler mouse motor neuron disease. Neuromusc Disord. 1995; 5: 383–90
- Ikeda K, Iwasaki Y, Kinoshita M. Neuronal nitric oxide synthase inhibitor, 7-nitroindazole, delays motor dysfunction and spinal motor neurons degeneration in the wobbler mouse. J Neurol Sci. 1998; 160: 9–15
- Yoshida M. Potential role of statins in inflammation and atherosclerosis. J Atheroscler Thromb. 2003; 10: 140–4
- Di Napoli P, Taccadi AA, Oliver M, de Caterina R. Statins and stroke: evidence for cholesterol-independent effects. Eur Heart J. 2002; 23: 1908–21
- Chen J, Zang ZG, Li Y, Wang Y, Wang L, Jiang H, et al. Statins induces angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol. 2003; 53: 743–51
- Iwasaki Y, Ikeda K, Kano O, Kawabe K, Hirano K. Atorvastatin protects spinal motor neurons from glutamate mediated neurotoxicity. Ann Neurol. 2005; 62(Suppl 9)S12
- Iwasaki Y, Ikeda K, Kano O, Kawabe K, Murata K. Atorvastatin protects spinal motor neuron death from axotomy induced neuronal death. Ann Neurol. 2007; 62(Suppl 11)S61
- Mitsumoto H, Bradley WG. Murine motor neuron disease (the wobbler mouse): degeneration and regeneration of the lower motor neuron. Brain. 1982; 105: 811–34
- Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar J-L, Bonnefont-Rousselot D, Bittar R, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008; 70: 1004–9
- Meisler MH, Russ C, Montgomery KT, Greenway M, Ennis S, Hardiman O, et al. Evaluation of the Golgi trafficking protein VPS54 (wobbler) as a candidate for ALS. Amyotroph Lateral Scler. 2008; 9: 141–8